BRIEF—Positive Phase III IMpower130 study for Roche's Tecentriq in NSCLC

Swiss pharma giant Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS).

The combination of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) helped people live significantly longer compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC).

In addition, the Tecentriq combination reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone.

The safety for the Tecentriq and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination.

These data will be presented at an upcoming oncology congress.

“The results of the IMpower130 study add to the growing evidence showing the clinical benefit of Tecentriq-based combinations in the treatment of advanced non-squamous non-small cell lung cancer,” said Sandra Horning, Roche’s chief medical officer and head of global product development.

Currently, Roche has eight Phase III lung cancer studies underway evaluating Tecentriq alone or in combination with other medicines.

This is the third positive Phase III study evaluating Tecentriq alone or in combination to demonstrate an OS benefit for people with NSCLC.